What Ventor Treats: Main Uses and Benefits

Ventor provides targeted support for symptom management in situations involving acute discomfort and inflammation. Its role is focused on managing a combination of symptoms that frequently cluster together in short-term, distressing episodes.

The medication is used for the treatment of acute pain and the symptomatic treatment of primary dysmenorrhoea (menstrual cramping). It is commonly used when symptoms may intensify temporarily and interfere with daily functioning.

The primary therapeutic benefit is to contribute to easing the overall symptom load in conditions presenting with acute episodes. The medication is relevant for easing discomfort related to symptoms of inflammatory or irritative states such as those accompanying musculoskeletal issues, including sprains, strains, or short-term relief for painful osteoarthritis flare-ups. Furthermore, it helps address symptoms related to systemic imbalance, including the management of elevated body temperature (fever). The supportive relief may assist with maintaining functional stability during disruptive episodes.

Quick Fact: Symptomatic Support for Acute Pain

Regulatory References

1. European Medicines Agency

This section outlines the populations for whom use of Ventor is defined, based on official regulatory eligibility criteria from the investigational study (NCT06759389). Ventor is currently an investigational product, and these criteria define who is eligible for the clinical study, not general use.

Eligibility Scope

Classification	Rules and Restrictions
Populations Allowed	Adults aged 18 to 75 years (inclusive) who present with non-traumatic IHCA (In-Hospital Cardiac Arrest) and are at least four feet in height.
Age-Related Rules	Use is strictly limited to the adult and older adult population, 18 Years to 75 Years.
Condition-Specific Rules	Must not have a known history of esophageal disease (e.g., Varices, Cancer, Strictures), facial/perforating neck trauma, or upper/lower airway obstruction.

Formal Exclusion and Contraindications

Populations that must not use Ventor in the context of the clinical study include:

• Patients with a valid Do-Not-Attempt-Resuscitation (DNAR) order or those currently intubated with an endotracheal tube (ET).
• Individuals with obvious signs of irreversible death (e.g., rigor mortis, decomposition).
• Pregnant patients (formal exclusion for known vulnerable subjects).
• Patients with injury causes like blunt, penetrating, or burn-related trauma, drowning, or electrocution.
• Individuals currently on the chemotherapy medications Oxaliplatin, Leucovorin, or Fluorouracil.

Ventor, which contains Nimesulide, has documented interaction patterns that necessitate restrictions when co-administering certain medicinal products and substances, as established in regulatory documents such as the European Medicines Agency (EMA) Summary of Product Characteristics.

Interaction Classifications (High-Level)

Classification	Description (as defined in official documents)
Interaction severity classification:	Contraindicated (e.g., severe coagulation disorders with anticoagulants, concomitant hepatotoxic drugs/alcohol abuse); Not Recommended (e.g., simultaneous use of other NSAIDs); Caution/Monitoring Required (e.g., co-administration with Lithium or Methotrexate).
Interaction-context constraints:	Coagulation status should be monitored closely if combination with anticoagulants cannot be avoided. Caution for co-administration with Methotrexate is tied to a 24-hour window around the dose.

Official Interaction Statements

• Nimesulide is formally documented as an inhibitor of CYP2C9, an interaction mechanism that may lead to increased plasma concentrations of other medicines that are substrates of this enzyme.
• The combination with Warfarin or similar anticoagulant agents presents an officially noted increased risk of bleeding complications.
• Co-administration of Nimesulide with Lithium may result in a reduction of lithium clearance and consequently elevated plasma levels of Lithium.
• Caution is required if used less than 24 hours before or after treatment with Methotrexate, due to the potential for an increase in the serum level of Methotrexate.
• Nimesulide may reduce the diuretic effect of Furosemide and requires caution in susceptible patients due to the risk of deterioration of renal function.
• Concomitant administration with known hepatotoxic drugs or alcohol abuse is an explicitly stated restriction that must be avoided.

The mechanism of Ventor is defined by the integrated pharmacodynamic actions of its single active ingredient, Nimesulide, which modulates the inflammatory cascade at multiple points.

---

Preferential COX-2 Inhibition and PGE2 Modulation

This domain covers the central mechanism: the molecule acts as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. COX-2 is an inducible enzyme that catalyzes the synthesis of Prostaglandin E2 ( PGE2), a crucial chemical mediator. By suppressing PGE2 production both peripherally and centrally, the mechanism results in a reduction of inflammatory signal transmission and resets the body’s elevated temperature set-point.

Non-Prostanoid-Mediated Inflammatory Control

The drug also engages mechanisms independent of COX enzyme inhibition to influence inflammatory dynamics. This involves scavenging damaging Reactive Oxygen Species (ROS) and modulating the function of immune cells like neutrophils, including restraining the release of destructive enzymes. This secondary action influences the total mechanistic output by attenuating downstream tissue reactions and the perpetuation of the chemical inflammatory cascade.

Ventor (Nimesulide) is taken via an oral administration route, utilizing the 100 mg tablet or the 100 mg granules for oral suspension. The standard regimen specifies a dose of 100 mg taken twice daily, once in the morning and once in the evening, which constitutes the maximum recommended daily intake of 200 mg. This consistent frequency is integral to the usage pattern.

Intake and Timing Protocol

Systemic formulations are administered after a meal, which governs the timing of consumption. Preparation of the granular form requires that the contents of the sachet be fully dissolved in a glass of water before consumption. Tablets are intended to be swallowed intact.

The entire course of treatment is characterized by a duration constraint. The treatment is intended for the shortest duration possible to address the acute condition and does not exceed 15 days of continuous administration. This limit is a fundamental component of the usage framework.

Population-Specific Constraints

Certain constraints exist for specific patient groups. The medicine is not for use in children under 12 years of age. For older adults, the standard twice-daily dose is generally maintained, and dose adjustment is typically not needed for patients with mild to moderate impairment of renal function.

Research Evidence / Overview of Studies for Ventor

This section provides an overview of the types of research studies that have been conducted with Ventor (Nimesulide), what aspects of the condition they explored, and where research remains limited. This information is intended to describe the available evidence landscape and does not offer medical advice or personal recommendations.

Evidence for Use in Acute Pain

Ventor was studied for use in managing various forms of acute pain. Research examined how symptoms change over time in adults and adolescents aged 12 and older. These were often short-term, randomized controlled trials (RCTs), where the drug was evaluated in comparison to a placebo or other pain relievers.

Studies examined outcomes related to physical discomfort. Findings describe patterns observed in the studies related to pain scores changing from the start of the study. Comparative studies evaluated differences in measured outcomes in observed populations. However, the follow-up durations were limited, typically lasting 15 days or less. Therefore, long-term effects are not fully established.

Evidence for Use in Primary Dysmenorrhoea

Ventor was evaluated in women and adolescents experiencing primary dysmenorrhoea, a condition characterized by fluctuating or episodic manifestations of menstrual pain. Short-term RCTs were conducted during periods of increased symptom activity. Studies examined outcomes capturing phases of heightened symptom activity, such as measuring differences in pain severity scores.

Findings describe patterns observed in the studies where reported discomfort scores were different from those in the placebo groups during the studied cycles. The follow-up durations were limited to only a few cycles, meaning that data are still emerging regarding the patterns of response over many cycles of intermittent use.

Long-Term Studies and Follow-up Duration

Research exploring short-term symptom changes is well-represented, covering treatment periods of 15 days or less. Evidence is limited regarding the durability of outcomes after the medication is stopped, or whether the pattern of change observed during the first few days was observed to remain consistent over an extended time. Long-term effects are not fully established, as clinical trials were designed to address acute, short-term use.

Evidence in Special Populations

Ventor was studied for use in adolescents aged 12 years and older for certain acute pain conditions. However, data for certain groups remain insufficient. For example, comparative evidence is lacking for children under the age of 12. Studies explored adult and older adult populations for painful osteoarthritis and acute pain, but findings for these subgroups are uncertain due to varied evidence quality.

What is Still Uncertain About Ventor

While research has contributed to the broader evidence landscape, several areas remain unclear. Long-term effects are not fully established, and sample sizes were modest in some comparative trials, meaning that subgroup findings are uncertain. Comparative evidence is lacking in some areas against newer classes of treatments. Therefore, more research is needed to address these evidence gaps and provide more detailed context on the patterns of use beyond short-term symptomatic relief.

Common questions about Ventor (FAQ)

Q: Is Ventor available over the counter, or is it prescription only?

A: Regulatory documents state that Ventor is officially classified as a prescription-only medicine. This means it must be obtained with a valid prescription from a qualified healthcare professional.

Q: What types of medications are known to interact with Ventor?

A: Official product information notes that Ventor may interact with several types of medications. These include certain anticoagulants (blood thinners like Warfarin), Lithium, Methotrexate, and the diuretic Furosemide. Caution is also required with medicines that are processed by the CYP2C9 enzyme, as well as drugs known to affect the liver or kidneys.

Q: Can Ventor be taken by people with kidney issues?

A: Use of Ventor is contraindicated, meaning it must be avoided, in cases of severe kidney impairment. For patients with other levels of kidney issues, official guidance indicates the need for caution. Regulatory information notes a potential risk of deterioration of kidney function associated with the medicine.

Q: Is Ventor safe to use during pregnancy or while breastfeeding?

A: Official regulatory documents state that the use of Ventor is contraindicated (must be avoided) throughout pregnancy, especially in the third trimester. This means that regulatory guidelines state the medicine should be avoided while breastfeeding. Additionally, regulatory bodies advise avoiding all medicines in this class (NSAIDs) from 20 weeks gestation onward due to potential risks to the developing fetus's kidneys.

Q: Does Ventor affect blood pressure?

A: Regulatory information indicates that medicines in the NSAID class, including Ventor, may be associated with an increase in blood pressure and fluid retention. Caution is also noted when Ventor is used alongside certain blood pressure or diuretic medicines.

Q: Are there any tests required before starting Ventor?

A: Due to the potential for liver-related adverse events, official documents suggest the need for appropriate clinical monitoring. Official guidance indicates that such tests may be part of the monitoring process, particularly when starting therapy or with limited-duration use.

Q: What are the most common side effects people notice when starting Ventor?

A: Regulatory data indicates that adverse events are frequently symptomatic. Among the side effects most often observed in clinical trials are gastrointestinal issues, such as epigastric pain (stomach discomfort) and nausea.

Q: How quickly does Ventor typically begin to show an effect?

A: Official reviews characterizing the medicine's properties suggest that the active ingredient in Ventor is known for a faster onset of action compared to some other medicines used for similar conditions.

Q: Do you have to take Ventor long-term?

A: No. Official use guidelines state that treatment is intended for the shortest duration possible to address the acute condition. It is mandated that the treatment should not exceed 15 days of continuous administration.

Q: What happens if I miss a dose of Ventor?

A: Official instructions indicate that if a dose is missed, it should be taken as soon as it is remembered, provided it is not almost time for the next scheduled dose. Official product information specifies that the dose should not be doubled to compensate for a missed dose.

Q: Can older adults use Ventor?

A: Yes, the standard twice-daily dose is generally maintained for older adults. However, official safety information notes caution is advised for this population, as they are particularly susceptible to certain adverse effects, requiring appropriate clinical monitoring.

Q: Is Ventor generally well-tolerated?

A: Official regulatory reviews have concluded that the overall benefit/risk profile is favorable when the medicine is used strictly according to guidelines. This includes limiting the duration of use and utilizing the medicine as a second-line treatment option.

Q: Can Ventor be split or crushed?

A: Official documents describe that tablets should be swallowed intact. If you have the granular form, the contents of the sachet must be fully dissolved in a glass of water before consumption.

Q: I'm feeling better, can I stop Ventor now?

A: The established treatment duration is limited to the shortest period necessary, not exceeding 15 days. Official guidelines state that the use and completion of the medicine should be managed by a healthcare provider.

Q: Is Ventor known to cause problems with the liver?

A: Official documents note a risk of serious liver toxicity, including rare reports of acute liver failure. Due to this risk, the medicine is contraindicated in patients with severe liver impairment or a history of liver-related reactions to the drug.

Q: Can Ventor be used if I am already taking several other medications?

A: Regulatory information confirms the medicine has a defined risk of interaction with several classes of drugs. Official documents indicate that the use of multiple medications requires medical assessment for potential risk and monitoring.

Q: What is the role of Ventor in a full treatment plan?

A: Official guidelines state that this medicine is intended for use as a second-line treatment for specific acute conditions. This means it is typically utilized when other initial medicines or therapies have not provided sufficient relief.

Q: Is the main use of Ventor different from what people commonly use it for?

A: The officially approved use of Ventor is limited to the treatment of acute pain and primary dysmenorrhoea (menstrual pain). Its approved function is strictly defined as a second-line treatment option for short-term relief.

Q: How long does Ventor stay in your system after you stop taking it?

A: Pharmacokinetic data from regulatory documents indicate that the elimination half-life of the active ingredient is typically between 1.8 and 4.7 hours. The medicine is eliminated from the body relatively quickly after the final dose.

Q: Are there different strengths of Ventor tablets available?

A: The medicine is supplied in various forms and strengths, most commonly as a 100 mg tablet and as granules for oral suspension. In some markets, different strengths, such as 200 mg capsules or a suspension form, may also be available.

Official Storage and Disposal Requirements

Regulatory documentation strictly defines the conditions necessary to store and dispose of Ventor (Nimesulide).

Storage Domain	Required Condition
Temperature & Protection	Store below 25 C in a tightly closed container; protect the product from heat and moisture.
Child Safety	The medication must be stored locked up and kept out of the sight and reach of children and pets.
Product Stability	Do not use the medicine after the expiration date printed on the original packaging.

Disposal must adhere to official guidelines. The preferred method is a drug take-back program or an authorized pharmaceutical waste collector. It is mandated that the medicine should not be released into the environment by throwing it down a sink or toilet.